Fabio Pastorino
G. Gaslini Children's Hospital
National Cancer Institute
Genoa
Italy
[email]@ospedale-gaslini.ge.it
Name/email consistency: high
- Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor. Pastorino, F., Loi, M., Sapra, P., Becherini, P., Cilli, M., Emionite, L., Ribatti, D., Greenberger, L.M., Horak, I.D., Ponzoni, M. Clin. Cancer Res. (2010)
- Recent advances in targeted anti-vasculature therapy: the neuroblastoma model. Pastorino, F., Di Paolo, D., Loi, M., Becherini, P., Caffa, I., Zorzoli, A., Marimpietri, D., Carosio, R., Perri, P., Montaldo, P.G., Brignole, C., Pagnan, G., Ribatti, D., Allen, T.M., Ponzoni, M. Curr. Drug. Targets (2009)
- Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Pastorino, F., Di Paolo, D., Piccardi, F., Nico, B., Ribatti, D., Daga, A., Baio, G., Neumaier, C.E., Brignole, C., Loi, M., Marimpietri, D., Pagnan, G., Cilli, M., Lepekhin, E.A., Garde, S.V., Longhi, R., Corti, A., Allen, T.M., Wu, J.J., Ponzoni, M. Clin. Cancer Res. (2008)
- Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin. Pastorino, F., Mumbengegwi, D.R., Ribatti, D., Ponzoni, M., Allen, T.M. J. Control. Release (2008)
